Navigation Links
WuXi PharmaTech Announces Appointment of Walter Kwauk to Board
Date:8/8/2014

SHANGHAI, Aug. 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of Walter Teh-Ming Kwauk as an independent director to the Board of Directors. Mr. Kwauk will serve on the Audit Committee. 

Mr. Kwauk is currently a senior consultant at Motorola Solutions (China) Co., Ltd. He serves as a director of Thunder Power Co. Ltd.; Sinosoft Technology Group Ltd., of which he serves as chairman of the audit committee; China Fordoo Holdings Ltd., of which he serves as chairman of the audit committee; and several private companies. He was formerly a director of Alibaba.com Ltd. Mr. Kwauk worked for KPMG from 1977 to 2002 and held a number of senior positions, including the general manager of KPMG's joint venture accounting firm in Beijing, the managing partner in KPMG's Shanghai office, and a partner in KPMG's Hong Kong office. He is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Kwauk received a B.S. and a licentiate's degree in accounting from the University of British Columbia.

"I am very pleased to join the board of WuXi PharmaTech, a company well-known as a leader in pharmaceutical R&D services," said Mr. Kwauk. "I look forward to working with the other board members to help WuXi grow."

"We are delighted to have the benefit of Walter's experience in corporate governance and in accounting and auditing matters," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "With his help, WuXi will continue to advance in its mission to build a comprehensive, integrated open-access R&D services platform."

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For further information please contact:

Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
ron_aldridge@wuxiapptec.com

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release
2. WuXi PharmaTech Provides Update of 2013 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
3. Winners of WuXi PharmaTech Awards Inducted into Prestigious Academies
4. WuXi PharmaTech Presents 2013 Life Science and Chemistry Awards
5. WuXi PharmaTech to Partner with Pharmacyclics
6. WuXi PharmaTech Announces Third-Quarter 2013 Results
7. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
8. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
9. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
10. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
11. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017 Following an initial ... praised the Food and Drug Administration,s (FDA,s) final ... Drug Products by Pharmacies and Outsourcing Facilities." In ... limitation on pre-packaging -- which would have put ... to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... January 17, 2017 ReportsnReports.com adds "Anaphylaxis ... provides an overview of the Anaphylaxis,s therapeutic pipeline with comprehensive ... analysis at various stages, therapeutics assessment by drug target, mechanism ... along with latest updates, and featured news and press releases. ... Complete ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, ... Forecast to 2021" report to their offering. ... The global active pharmaceutical ingredients ... USD 157.95 Billion in 2016, growing at a CAGR of 6.3% ...
Breaking Medicine Technology:
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... Livionex, ... the results of a double blind clinical study for its dental gel that shows ... leading national brand of toothpaste containing triclosan. The study was conducted at the Beckman ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... from two offices in Tyler, has announced the latest beneficiary of their thriving ... Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Today, FloSports ... Wrestling announced a new agreement as part of a long-term extension of their ... and includes the airing of some of the sport’s premier events exclusively on FloWrestling.com ...
(Date:1/16/2017)... ... January 17, 2017 , ... Recently, patients and staff ... Michigan, joined other volunteers and organizations in support of the annual Binder Park Zoo ... families dressed up in colorful costumes of all designs coming out to enjoy games, ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF ... in Las Vegas, Booth #2809. The SHOT Show is the shooting, hunting and ...
Breaking Medicine News(10 mins):